Massachusetts Financial Services Co. MA Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Massachusetts Financial Services Co. MA increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 4.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,160,027 shares of the biopharmaceutical company’s stock after purchasing an additional 139,491 shares during the quarter. Massachusetts Financial Services Co. MA owned about 1.06% of Amicus Therapeutics worth $33,749,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. OLD Second National Bank of Aurora purchased a new position in Amicus Therapeutics during the third quarter worth about $26,000. Hazlett Burt & Watson Inc. grew its position in Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares in the last quarter. Blue Trust Inc. grew its position in Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics during the third quarter worth about $32,000. Finally, Headlands Technologies LLC purchased a new position in Amicus Therapeutics during the second quarter worth about $89,000.

Wall Street Analyst Weigh In

FOLD has been the subject of several recent analyst reports. Bank of America boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Guggenheim upped their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 16th. Finally, JPMorgan Chase & Co. upped their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.63.

Amicus Therapeutics Trading Up 0.6 %

NASDAQ FOLD opened at $9.72 on Tuesday. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The stock has a 50-day moving average of $10.80 and a 200-day moving average of $10.59. The firm has a market cap of $2.90 billion, a PE ratio of -28.59 and a beta of 0.68.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 30,401 shares of company stock valued at $352,038. Insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.